Contrarian Corpus
activist conference presentation initial thesis
2024-10-01 · 74 pages

Pfizer Inc. PFE

Pfizer destroyed $20-60bn of value since 2019 despite a $40bn COVID windfall; Starboard wants the board to hold Bourla accountable for peer-median R&D/M&A returns.

N 5 Narrative
V 4 Visual
C 4 Craft
Source URL unavailable

Thesis

Pfizer has dramatically underperformed peers and the S&P 500 since 2019, losing an estimated $20-60bn of shareholder value even after a roughly $40bn COVID cash windfall. Starboard argues the root cause is collapsing R&D and M&A productivity: CEO Albert Bourla publicly committed in 2018-2019 to delivering '15 potential blockbusters' by 2022 but most of those programs missed, while subsequent deals including the $43bn Seagen acquisition and the $5.4bn Global Blood Therapeutics purchase (whose lead drug Oxbryta was pulled in September 2024) were struck at 3.3-5.1x peak sales versus a 2.4x market median. Consensus implies just a 15% revenue return on $128bn of cumulative R&D plus M&A spend, worst in the peer group against a 38% median. Starboard is pressing the board to enforce accountability and drive 2030 revenue to $79bn and EPS above $4.25.

SCQA

Situation

Pfizer is one of the world's largest pharmaceutical companies, operating across primary care, specialty care, and oncology, generating roughly $58bn of 2023 revenue and playing a critical public-health role through its COVID-19 vaccine and Paxlovid antiviral.

Complication

Since 2019 Pfizer's stock has returned minus 13% while peers rallied 120%; despite a $40bn COVID windfall, management missed its '15 blockbusters in 5 years' pledge, overpaid on ~$70bn of M&A, and posted worst-in-class R&D returns.

Resolution

The board must actively hold management accountable for capital-allocation discipline on R&D and M&A, measuring success by revenue return on invested capital and demanding at minimum the 38% peer-median productivity rather than the current 15%.

Reward

Achieving peer-median returns implies ~$79bn of 2030 revenue and adjusted EPS above $4.25, supporting a re-rating from today's 10x P/E toward the 14x peer median and roughly doubling the share price.

The three reasons

  1. 1

    Pfizer lost $20-60bn of market value since 2019 despite a ~$40bn COVID cash windfall

  2. 2

    CEO Bourla's 2018 pledge of '15 blockbusters in 5 years' has largely failed to materialize

  3. 3

    15% revenue return on $128bn R&D and M&A spend - worst-in-class vs 38% peer median

Primary demands

  • Board must actively hold management accountable for R&D and M&A capital-allocation returns
  • Drive expected revenue return on R&D plus M&A from 15% to at least the 38% peer median
  • Achieve ~$79bn of 2030 revenue and >$4.25 adjusted EPS (ex-COVID)
  • Restore management credibility after missed 2024 guidance and failed deals (e.g. Oxbryta/GBT)
  • Apply greater discipline on future M&A multiples and deal selection

KPIs cited

5-year Total Shareholder Return (since 12/31/2018)
Pfizer (13%) vs S&P 500 +152% and NYSE Arca Pharma +120% - 132pts of underperformance
Market value lost since 2019
~$20-60bn ($21bn market cap decline + ~$40bn COVID benefit foregone)
Incremental COVID free cash flow 2021-2022
~$40bn above 2020 baseline ($30bn FY21 + $26bn FY22 vs $8bn FY20)
P / CY25 EPS multiple
PFE 10x vs peer median 14x (LLY 39x, NVO 27x on top end)
Cumulative M&A spend since pandemic
~$70bn (SGEN $43.4bn, Biohaven $12.9bn, Arena $6.3bn, GBT $5.3bn, ReViral $0.4bn)
EV / Peak Sales on M&A
3.3x on management estimates / 5.1x on sellside consensus vs 2.4x 10-year industry median
Revenue return on R&D + M&A 2019-2023
PFE 10% (15% ex-COVID) vs peer median 38% - worst in class
Cumulative R&D + M&A investment 2019-2023
$128bn ($46bn R&D + $82bn M&A, ex $4bn COVID R&D)
Consensus 2023-2030 revenue growth
PFE -3% (ex-COVID +9%) vs peer median +27%
FY23 COVID sales guidance miss
$12.5bn actual vs $21.5bn initial guidance - $9bn miss
FY24 initial adjusted EPS guidance vs consensus
$2.15 guide vs $3.20 consensus - over $1.00/share miss
'15 potential blockbusters by 2022' outcome
3 approved, 2 discontinued for futility, several materially below $1bn blockbuster threshold (Bavencio ~$270mm, Cibinqo ~$565mm by 2030, Litfulo ~$660mm by 2030)
2030 revenue required to reach peer-median return
$79bn pro forma vs consensus $50bn - $29bn incremental growth required

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • Eli Lilly and Novo Nordisk GLP-1 franchises (Mounjaro/Zepbound, Ozempic/Wegovy) as peer innovation benchmark
  • Prevnar 20 as example of Pfizer's own prior innovation success

Notable slides (6)

Notes

Classic Starboard deck structure: praise management for COVID achievements up front, then systematically dismantle the record using management's own quotes (Bourla's 'best pipeline ever' and '15 blockbusters in 5 years' at pp. 13-18) and peer-gap charts. Argument built around four pillars: (A) lack of internal innovation 2019-2023, (B) lack of expected future innovation (including missed GLP-1 opportunity), (C) overpaid capital allocation (~$70bn M&A at 3.3-5.1x peak sales), (D) forecasting/budgeting failures (FY23 COVID miss, FY24 EPS miss). Closing 'conclusion' section re-litigates the same points and frames ask as board-level accountability rather than specific board seats or breakup - softer than a proxy fight deck. PDF is sourced from 10xEBITDA.com (watermark visible on all slides); presented at the October 2024 13D Monitor Active-Passive Investor Summit. No explicit stake percentage disclosed in the deck itself. Deck builds heavy use of CEO quote contradiction as its core rhetorical device - unusually quote-dense for a Starboard presentation.